Niowave and Novartis (NOVN SW) enter global actinium-225 supply agreement to advance next-generation cancer therapies
Context
Niowave's agreement with Novartis underscores a strategic move in the pharmaceutical sector towards enhancing cancer treatment options. This could position Novartis favorably within the biotechnology landscape, potentially indicating a focus on innovative therapies that might attract investor interest and impact sector sentiment.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#SWITZERLAND#NOVARTIS AG#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#SWISS MARKET INDEX#NOVN#EUROPEAN EQUITIES